- Home
- IRBT vs CTNM Comparison
IRBT vs CTNM Comparison
Compare IRBT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRBT
- CTNM
- Stock Information
- Founded
- IRBT 1990
- CTNM 2009
- Country
- IRBT United States
- CTNM United States
- Employees
- IRBT N/A
- CTNM N/A
- Industry
- IRBT Consumer Electronics/Appliances
- CTNM
- Sector
- IRBT Consumer Discretionary
- CTNM
- Exchange
- IRBT Nasdaq
- CTNM Nasdaq
- Market Cap
- IRBT 130.0M
- CTNM 142.3M
- IPO Year
- IRBT N/A
- CTNM 2024
- Fundamental
- Price
- IRBT $4.88
- CTNM $5.77
- Analyst Decision
- IRBT Hold
- CTNM Strong Buy
- Analyst Count
- IRBT 1
- CTNM 4
- Target Price
- IRBT N/A
- CTNM $22.50
- AVG Volume (30 Days)
- IRBT 2.9M
- CTNM 366.4K
- Earning Date
- IRBT 08-05-2025
- CTNM 08-12-2025
- Dividend Yield
- IRBT N/A
- CTNM N/A
- EPS Growth
- IRBT N/A
- CTNM N/A
- EPS
- IRBT N/A
- CTNM N/A
- Revenue
- IRBT $633,404,000.00
- CTNM N/A
- Revenue This Year
- IRBT $3.23
- CTNM N/A
- Revenue Next Year
- IRBT $28.90
- CTNM N/A
- P/E Ratio
- IRBT N/A
- CTNM N/A
- Revenue Growth
- IRBT N/A
- CTNM N/A
- 52 Week Low
- IRBT $1.76
- CTNM $3.35
- 52 Week High
- IRBT $13.45
- CTNM $21.58
- Technical
- Relative Strength Index (RSI)
- IRBT 61.53
- CTNM N/A
- Support Level
- IRBT $4.28
- CTNM N/A
- Resistance Level
- IRBT $5.52
- CTNM N/A
- Average True Range (ATR)
- IRBT 0.54
- CTNM 0.00
- MACD
- IRBT 0.07
- CTNM 0.00
- Stochastic Oscillator
- IRBT 65.78
- CTNM 0.00
About IRBT iRobot Corporation
iRobot Corp is a United state based consumer robot company. It designs and builds robots that assist consumers with the solutions for the activities to be carried out both inside and outside of the home. The company's consumer robot comprises a portfolio of solutions which includes cleaning, mapping and navigation, human-robot interaction, and physical solutions. The company operates in the business segment of Consumer robots. The consumer robot products are provided to the consumers by retail businesses and online stores. The company derives its revenue from the product sales. It sells the products across the United States and around the world.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.